Back to Press Releases

Impel NeuroPharma Closes $67.5 Million Series D Financing

December 6, 2018

Crossover Financing to Advance Clinical Development of Central Nervous System Assets in Migraine, Parkinson’s Disease and Acute Agitation

SEATTLE, Dec. 6, 2018 /PRNewswire/ — Impel NeuroPharma (“Impel” or the “Company”), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (“CNS”) disorders with unmet medical needs, today announced that it has completed a Series D financing totaling $67,500,000. The investment is co-led by KKR and Norwest Venture Partners (“Norwest”), with participation from existing investors, Vivo Capital, 5AM Ventures and venBio Partners.

In connection with the financing Dr. Robert Mittendorff, Partner at Norwest, and Ali Satvat, Member at KKR, will join the Impel Board of Directors.

This financing will enable Impel to accelerate its existing clinical development portfolio in CNS disorders. Impel is currently investigating three programs leveraging its novel Precision Olfactory Delivery, or POD®, device technology: INP104 in a Phase 3 trial for the treatment of acute migraine headache, INP103 in a Phase 2 trial for the reversal of OFF episodes in Parkinson’s disease and INP105 in a Phase 1 trial for the treatment of acute agitation in bipolar I and schizophrenia disorders.

“We are delighted to have the support of this exceptional group of both new and existing investors. Dr. Mittendorff and Mr. Satvat will be tremendous assets as new members of Impel’s Board of Directors and we believe that this investment is a testament to the strength of our POD® technology, our clinical programs and our management team,” said Jon Congleton, Chief Executive Officer of Impel. “With three product candidates progressing through various stages of clinical development in 2018, it has been an exciting year for Impel, and this financing confirms the value that we are generating with our clinical programs.”

“We are excited to have co-led this financing round with KKR and look forward to helping Impel reach its goals as the Company progresses the development of these novel investigative therapies,” said Dr. Mittendorff. “Norwest shares in Impel’s belief that the Company’s pipeline has the potential to bring important new treatments to the market for the CNS community.”

“We are thrilled to contribute to the development of innovative solutions that may enhance the lives of patients with CNS disorders,” said Mr. Satvat. “Impel’s proprietary, novel platform has the potential to transform intranasal drug delivery, significantly improving the range of treatment options for people living with acute migraine, acute agitation and Parkinson’s disease.”

About Impel NeuroPharma
Impel NeuroPharma, Inc., is a privately-held, Seattle-based biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Impel NeuroPharma is currently investigating INP104 (POD-DHE) for acute migraine headache, INP103 (POD-levodopa) for reversal of OFF episodes in Parkinson’s disease and INP105 (POD-olanzapine) for acute agitation in schizophrenia and bipolar disorders.

Impel’s products utilize its novel, nasal drug-delivery Precision Olfactory Delivery, or POD™, device technology to deliver liquid or dry powder forms of drug to the upper nasal cavity in a consistent and predictable manner.

IMPEL, POD and the IMPEL Logo are trademarks of Impel NeuroPharma, Inc. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com.

About Precision Olfactory Delivery™ or POD™ Devices
Impel NeuroPharma’s proprietary POD™ intranasal drug delivery device is designed to deliver drugs to the richly-vascularized upper nasal cavity to achieve superior biodistribution and bioavailability of both small molecules and biologic drugs. By consistently and predictably delivering therapeutics to the upper nasal cavity, the POD nasal delivery device may improve overall bioavailability of drugs. The POD device also has the potential for nose-to-brain delivery via the olfactory and trigeminal nerves. Impel has developed dry powder and liquid compatible POD devices to improve upon current treatment options for central nervous system (CNS) disorders.

Contact:
Melyssa Weible
Elixir Health Public Relations
Ph: (1) 201-723-5805
E: mweible@elixirhealthpr.com


Download PDF

Back to Press Releases

Media Contacts

Americas

Kristi Huller
Julia Kosygina
Liidia Liuksila
Telephone: +1 (212) 750-8300

Email: media@kkr.com

EMEA

Annabel Arthur
Miles Radcliffe-Trenner
Julia Leeger
Telephone: +44 20 7839 9800

Email: kkrpr-uk@kkr.com

Asia-Pacific

Wei Jun Ong
Telephone: +852 3602 7335

Email: media@kkr.com

Investor Relations

‍Craig Larson
Telephone: +1 (877) 610-4910
Outside US: +1 (212) 230-9410
Facsimile: +1 (212) 750-0003
Email: Investor-Relations@kkr.com

×

Listen to webcast

This presentation contains certain forward-looking statements pertaining to KKR & Co. Inc. and its consolidated subsidiaries (collectively “KKR”), including certain investment funds, vehicles and accounts that are managed by KKR (each, a “fund”). Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. The forward-looking statements are based on KKR’s beliefs, assumptions and expectations of its future performance, taking into account all information currently available to it. These beliefs, assumptions and expectations can change as a result of many possible events or factors, not all of which are known to KKR or are within its control. If a change occurs, KKR’s business, financial condition, liquidity and results of operations, including but not limited to, assets under management, fee paying assets under management, after-tax distributable earnings, capital invested, syndicated capital, uncalled commitments, cash and short-term investments, fee related earnings, fee and yield segment EBITDA, core interest expense and book value, may vary materially from those expressed in the forward-looking statements. The following factors, among others, could cause actual results to vary from the forward-looking statements: whether KKR realizes all or any of the anticipated benefits from converting to a corporation and the timing of realizing such benefits; whether there are increased or unforeseen costs associated with the conversion, including any adverse change in tax law; the volatility of the capital markets; the general volatility of the capital markets; failure to realize the benefits of or changes in KKR’s business strategies including the ability to realize the anticipated synergies from acquisitions or strategic partnerships or other transactions; availability, terms and deployment of capital; availability of qualified personnel and expense of recruiting and retaining such personnel; changes in the asset management industry, interest rates or the general economy; underperformance of KKR's investments and decreased ability to raise funds; and the degree and nature of KKR’s competition. All forward-looking statements speak only as of the date they are made. KKR does not undertake any obligation to update any forward-looking statements to reflect circumstances or events that occur after the date on which such statements were made except as required by law. In addition, KKR’s business strategy is focused on the long-term and financial results are subject to significant volatility.

Additional information about factors affecting KKR, including a description of risks that may be important to a decision to purchase or sell any common or preferred stock of KKR & Co. Inc., can be found in KKR & Co. Inc.’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and its other filings with the SEC, which are available at www.sec.gov.

I understand  |   Go back
×

Listen to Presentation

Before viewing this presentation, please acknowledge your understanding that it has been prepared for KKR & Co. Inc. (NYSE:KKR) for the benefit of its public stockholders and is not intended to be a solicitation or sale of any of the securities, funds or services that it may discuss. Please click on "I understand" to view the presentation.

I understand  |   Go back